CClinicalTrials.gg
CompletedNCT05594056Updated Apr 27, 2023

Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia.

An interventional study of Transorbital ultrasound of the optic nerve sheet in Preeclampsia Severe, sponsored by Saint Thomas Hospital, Panama. Completed at 1 site in Panama. Open to female participants aged 15 Years to 44 Years. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by Saint Thomas Hospital, Panama · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
15 Years to 44 Years
Sex
Female
01

Study summary

The neurological alterations associated with preeclampsia depend on cerebral autoregulation, a theory that outlines the mechanisms by which the nervous system controls cerebral perfusion. However, with the loss of autoregulation, increased blood flow, edema and eventually increased intracranial pressure are triggered and may be translated into neurological manifestations such as symptoms of vasospasm, one of the criteria for severity in preeclampsia.

Nervous system manifestations frequently found in preeclampsia are headache, blurred vision, scotomas and hyperreflexia. Although uncommon, temporary blindness (lasting a few hours to a week) may also accompany severe preeclampsia and eclampsia.

The optic nerve, as part of the central nervous system, is surrounded by cerebrospinal fluid and dura mater, which forms the optic nerve sheath. Due to the connection with the intracranial subarachnoid space, the diameter of the optic nerve sheath is influenced by variations in cerebrospinal fluid pressure. Increased intracranial pressure is transmitted to the subarachnoid space surrounding the optic nerve, causing its expansion.

Recent studies suggest that an optic nerve sheath diameter greater than 5 mm correlates 100% with ICP (intracerebral pressure) greater than 20 mm Hg. Due to the simple nature of the test and the limited time required to perform it, it is an ideal non-invasive test to assess changes in mental status, severe headache, and to take the necessary measures aimed at reducing intracranial pressure.

The diagnosis of elevated intracranial pressure is challenging and critical, because early recognition and treatment are essential to prevent brain damage or death since preeclampsia with severe data remains one of the most frequent complications in our institution.

These values are not taken from the obstetric population, so this study proposes the description of a standard value for the pregnant population. There are few studies that describe a value to help us define cases of this pathology and correlate it with the signs and symptoms of severity in patients with preeclampsia.

02

Conditions studied

  • Preeclampsia Severe

Browse trials for

Keywords

  • Severe preeclampsia
  • Optic nerve sheet
  • Intracranial pressure
03

In context

Pre-Eclampsia

882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.

This study's enrollment of 100 is close to the median of 110 across 468 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Saint Thomas Hospital, Panama is the lead sponsor of 36 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 15-44 years.
  • Gestational age between 34-40 weeks of gestation.

Exclusion criteria

Exclusion Criteria:

  • Eye disease (Glaucoma, diabetic neuropathy, optic neuritis).
  • Nervous disorders.
  • Psychiatric disorders
  • Diabetes
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Preeclampsia

    Patients with severe preeclampsia and gestational age between 34-40 weeks.

    Procedure: Transorbital ultrasound of the optic nerve sheet

  • Active comparator
    Control

    Patients with normal gestations between 34-40 weeks.

    Procedure: Transorbital ultrasound of the optic nerve sheet

Interventions

  • ProcedureTransorbital ultrasound of the optic nerve sheet

    Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).

06

What researchers measure

Primary outcomes

  1. Optic nerve sheet measurement

    The diameter of the optic nerve sheath was measured three millimeters behind the eyeball, and one axis perpendicular to the optic nerve. Three measurements were taken in each eye. The resulting six measurements were averaged to give a mean of the optic nerve sheet measurement, to minimize measurement variability.

    Time frame: 24 hours

07

Study locations

1 site
  • Saint Thomas H
    Panama, Panama
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05594056
Lead sponsor
Saint Thomas Hospital, Panama
Responsible party
Osvaldo A. Reyes T. (Chairman of Research Department, Saint Thomas Hospital, Panama) — Principal investigator
First posted
Oct 26, 2022
Start date
Oct 21, 2022
Primary completion
Dec 31, 2022
Completion
Jan 31, 2023
Last update
Apr 27, 2023

Study contacts

Osvaldo Reyes, MD
study chair · Saint Thomas Hospital, Panama

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion